Optimi Health Corp. reports on its role as a commercial-stage pharmaceutical manufacturer of regulated botanical wellness drug products, including GMP-manufactured MDMA capsules and natural botanical research compound capsules. Company updates commonly cover Health Canada-licensed production, export permits, finished dosage forms, and supply into regulated medical access pathways.
Recurring news themes include shipments and clinical use under Australia’s Authorised Prescriber Scheme, products supplied for PTSD and treatment-resistant depression, access through Canada’s Special Access Program, and initiatives to expand manufacturing capability to ibogaine. Optimi also reports capital-market actions, financing documents, investor presentations, and regulatory readiness tied to its cross-border commercial strategy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Optimi Health Corp. (OTCQX: OPTHF) has announced a significant long-term distribution agreement with Mind Medicine Australia to supply GMP-grade MDMA and psilocybin for therapeutic use in Australia. This follows the Australian government's reclassification allowing authorized psychiatrists to prescribe these substances for treatment-resistant conditions starting July 1, 2023. Key aspects include signed purchase orders for medical-grade substances manufactured under GMP protocols at Optimi's Health Canada licensed facility. This agreement represents Optimi's first international sales of these products, supporting the push for expanded access to psychedelic therapies in response to the mental health crisis.
Optimi Health Corp. has submitted a clinical trial application for a Phase I study to evaluate the safety of its natural psilocybin standardized extract and proprietary MDMA drug candidate in healthy therapists. This trial, conducted in collaboration with ATMA Journey Centers, is the first to compare the effects of both substances. The study aims to enroll 25 participants across five groups, assessing safety and physiological markers. The company aims to address the significant shortage of therapists trained in psychedelic therapy as it progresses towards commercialization.